Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
435.32
+2.72 (0.63%)
NASDAQ · Last Trade: Nov 11th, 10:17 AM EST
News & Press Releases
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · November 11, 2026
Kaplan Fox Notifies Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Investigation Into Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 10, 2026
NASDAQ: MDGL Investigation: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA - November 10, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
Via NewMediaWire · November 10, 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worrieschartmill.com
Via Chartmill · July 30, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations Investors are Encouraged to Contact the Firm
NEW YORK, NY - November 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
Via NewMediaWire · November 10, 2026
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 9, 2026
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 9, 2026
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 9, 2026
Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders lost $34.84 per share on November 3, 2026, when the stock fell 8.1% after the Company disclosed a whistleblower complaint filed by its former Senior Vice President, Head of Clinical Development. If you suffered a loss on your Madrigal investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · November 9, 2026
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Madrigal Pharmaceuticals, Inc. (“Madrigal” or “the Company”) (NASDAQ: MDGL) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · November 8, 2026
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 6, 2026
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · November 6, 2026
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop
Investors who lost money on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals, Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 6, 2026
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 8.1% Share Price Decline
Investors who suffered losses on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation comes after a November 3, 2026 disclosure concerning Madrigal Pharmaceuticals, Inc.
By The Law Offices of Howard G. Smith · Via Business Wire · November 6, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 6, 2026
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 5, 2026
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline
Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Madrigal Pharmaceuticals, Inc. on November 3, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · November 5, 2026
Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 5, 2026
Madrigal (MDGL) Q3 2026 Earnings Call Transcriptfool.com
Rezdiffra hits blockbuster status as net income turns positive for first time.
Via The Motley Fool · November 3, 2026
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Callmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to add patients and expand its prescriber base. Year-to-date net sales reached $1.1 billion, and the co
Via MarketBeat · November 3, 2026
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?fool.com
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Via The Motley Fool · September 10, 2026
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Offfool.com
Rezdiffra's biggest growth opportunity may still be ahead.
Via The Motley Fool · August 25, 2026
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expandsmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
Speaking at a Canaccord Genuity event, C
Via MarketBeat · August 15, 2026
Madrigal Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
The company sai
Via MarketBeat · July 30, 2026
3 Under-the-Radar Stocks to Buy and Holdfool.com
Sometimes, little-known stocks are worth buying.
Via The Motley Fool · July 10, 2026